UY32642A - Espironucleósidos uracílicos oxetánicos - Google Patents

Espironucleósidos uracílicos oxetánicos

Info

Publication number
UY32642A
UY32642A UY0001032642A UY32642A UY32642A UY 32642 A UY32642 A UY 32642A UY 0001032642 A UY0001032642 A UY 0001032642A UY 32642 A UY32642 A UY 32642A UY 32642 A UY32642 A UY 32642A
Authority
UY
Uruguay
Prior art keywords
phenyl
alkyl
optionally substituted
spironucleosids
oxethanic
Prior art date
Application number
UY0001032642A
Other languages
English (en)
Inventor
Van Hoof Steven Maurice Paula
Jonckers Tim Hugo Maria
Raboisson Pierre Jean-Marie Bernard
Vandyck Koen
Hu Lili
Tahri Abdellah
Original Assignee
Medivir Ab
Centocor Ortho Biotech Products L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab, Centocor Ortho Biotech Products L P filed Critical Medivir Ab
Publication of UY32642A publication Critical patent/UY32642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos de la fórmula I incluyendo cualquier estereoisómero posible de los mismos, en donde: R4 es un éster monofosfato o trifosfato; o R4 es R7 es fenilo opcionalmente sustituido, naftilo opcionalmente sustituido, o indolilo opcionalmente sustituido; R8 y R8`are hidrógeno, alquilo C1-C6, bencilo, o fenilo; o R8 y R8` forman cicloalquilo C3-C7; R9 es alquilo C1-C10, cicloalquilo C3-C7, fenilo o fenil-alquilo C1-C6, en donde la porción fenilo en el fenilo o en el fenil-alquilo C1-C6 está opcionalmente sustituida; o una sal o un solvato farmacéuticamente aceptable de los mismos; formulaciones farmacéuticas y el uso de los compuestos I como inhibidotes del VHC.
UY0001032642A 2009-05-14 2010-05-14 Espironucleósidos uracílicos oxetánicos UY32642A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09160215 2009-05-14

Publications (1)

Publication Number Publication Date
UY32642A true UY32642A (es) 2010-11-30

Family

ID=40823307

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032642A UY32642A (es) 2009-05-14 2010-05-14 Espironucleósidos uracílicos oxetánicos

Country Status (39)

Country Link
US (2) US8481510B2 (es)
EP (2) EP2511282B1 (es)
JP (2) JP5778135B2 (es)
KR (1) KR101806837B1 (es)
CN (1) CN102439024B (es)
AP (1) AP2783A (es)
AR (1) AR076579A1 (es)
AU (1) AU2010247439B2 (es)
BR (1) BRPI1010579A2 (es)
CA (1) CA2760329C (es)
CL (1) CL2011002859A1 (es)
CO (1) CO6440533A2 (es)
CR (1) CR20120297A (es)
CY (2) CY1114081T1 (es)
DK (2) DK2511282T3 (es)
EA (1) EA022084B1 (es)
EC (1) ECSP11011461A (es)
ES (2) ES2411086T3 (es)
HK (1) HK1166326A1 (es)
HN (1) HN2011003014A (es)
HR (2) HRP20130554T1 (es)
IL (1) IL215955A (es)
JO (1) JO3027B1 (es)
ME (1) ME01478B (es)
MX (1) MX2011012027A (es)
MY (1) MY157018A (es)
NI (1) NI201100197A (es)
NZ (1) NZ596073A (es)
PL (2) PL2511282T3 (es)
PT (2) PT2511282E (es)
RS (1) RS52822B (es)
SG (1) SG175981A1 (es)
SI (2) SI2511282T1 (es)
SM (2) SMT201300078B (es)
TW (1) TWI461432B (es)
UA (1) UA105790C2 (es)
UY (1) UY32642A (es)
WO (1) WO2010130726A1 (es)
ZA (1) ZA201108309B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
PT2638054E (pt) 2010-11-10 2015-03-02 Medivir Ab Fosforamidatos de nucleósidos de uracilo espirooxetano
WO2012062869A1 (en) * 2010-11-10 2012-05-18 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
AU2015252113B2 (en) * 2010-11-30 2017-05-04 Gilead Pharmasset Llc Compounds
JP6069215B2 (ja) * 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
BR112013026219A2 (pt) * 2011-04-13 2016-07-26 Gilead Sciences Inc análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral
AU2012358804B2 (en) * 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EA027929B1 (ru) * 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
AU2014225052B2 (en) * 2013-03-08 2016-11-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Novel nucleoside phosphoramidate compound and use thereof
CN105377868A (zh) 2013-04-12 2016-03-02 艾其林医药公司 用于治疗hcv的高活性核苷衍生物
CN104231023B (zh) * 2013-06-06 2019-02-05 南京汇诚制药有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
US20170165287A1 (en) * 2013-11-28 2017-06-15 Janssen Sciences Ireland Uc Crystal form of a nucleoside inhibitor of hcv
GEP20247600B (en) 2015-03-06 2024-02-26 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CA3088287A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4135716A1 (en) * 2020-04-14 2023-02-22 Janssen Pharmaceuticals, Inc. Spirocyclic nucleoside analogues for the treatment of hepatitis e

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539188B1 (en) * 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
CA2618335C (en) * 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
AU2007215114A1 (en) * 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان

Also Published As

Publication number Publication date
IL215955A (en) 2015-03-31
EP2511282B1 (en) 2014-04-02
CO6440533A2 (es) 2012-05-15
ES2477598T3 (es) 2014-07-17
EP2511282A1 (en) 2012-10-17
IL215955A0 (en) 2012-01-31
JP2015180692A (ja) 2015-10-15
SG175981A1 (en) 2011-12-29
EP2430035B1 (en) 2013-04-03
CY1115383T1 (el) 2017-01-04
RS52822B (en) 2013-10-31
KR101806837B1 (ko) 2017-12-08
NZ596073A (en) 2013-02-22
CY1114081T1 (el) 2016-07-27
PL2430035T3 (pl) 2013-08-30
PT2430035E (pt) 2013-05-22
US8481510B2 (en) 2013-07-09
US20120065156A1 (en) 2012-03-15
MY157018A (en) 2016-04-15
CR20120297A (es) 2012-10-25
CL2011002859A1 (es) 2012-07-20
AR076579A1 (es) 2011-06-22
TWI461432B (zh) 2014-11-21
AP2783A (en) 2013-10-31
JP2012526764A (ja) 2012-11-01
PL2511282T3 (pl) 2014-09-30
TW201100442A (en) 2011-01-01
EA201171406A1 (ru) 2012-05-30
ME01478B (me) 2014-04-20
MX2011012027A (es) 2012-02-28
HRP20140605T1 (hr) 2014-09-26
SI2511282T1 (sl) 2014-09-30
KR20120018355A (ko) 2012-03-02
HK1166326A1 (en) 2012-10-26
AU2010247439A1 (en) 2011-12-01
AU2010247439B2 (en) 2014-09-25
DK2430035T3 (da) 2013-05-27
CN102439024B (zh) 2014-09-17
ZA201108309B (en) 2013-04-24
US20130217648A1 (en) 2013-08-22
CN102439024A (zh) 2012-05-02
EP2430035A1 (en) 2012-03-21
JO3027B1 (ar) 2016-09-05
NI201100197A (es) 2012-05-28
PT2511282E (pt) 2014-07-11
ES2411086T3 (es) 2013-07-04
US8933052B2 (en) 2015-01-13
CA2760329A1 (en) 2010-11-18
HRP20130554T1 (en) 2013-07-31
SMT201300078B (it) 2013-09-06
ECSP11011461A (es) 2012-02-29
AP2011005958A0 (en) 2011-10-31
EA022084B1 (ru) 2015-10-30
DK2511282T3 (da) 2014-07-07
BRPI1010579A2 (pt) 2016-03-15
UA105790C2 (uk) 2014-06-25
SMT201400085B (it) 2014-09-08
JP5778135B2 (ja) 2015-09-16
WO2010130726A1 (en) 2010-11-18
CA2760329C (en) 2017-10-31
SI2430035T1 (sl) 2013-08-30
HN2011003014A (es) 2014-06-30

Similar Documents

Publication Publication Date Title
UY32642A (es) Espironucleósidos uracílicos oxetánicos
UY32308A (es) Nucleótidos uracil ciclopropílicos
UY31950A (es) Inhibidores de ciclopropil-polimerasa
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
UY32490A (es) Inhibidores de beta-secretasa
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
UY32759A (es) Inhibidores del virus de la hepatitis c
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
PE20142186A1 (es) Derivados biciclicos de pirazinona
AR073037A1 (es) Derivados de enfumafungina, utiles en la inhibicionde (1,3)-beta-d-glucano sintasa
AR088414A1 (es) Derivados sustituidos de indol
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
AR079267A1 (es) Derivados del tipo hexahidrociclopenta(b)pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR078984A1 (es) Pirazina sustituida con oxazolo (4,5-c) piridina
AR079265A1 (es) Derivados de azabiciclo(3.1.0)hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR074395A1 (es) Derivados de indol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6280059A1 (es) Nuevos derivados de azabiciclos (3.2.0) hept-3-ilo su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR078424A1 (es) Derivados de dihidroimidazoquinolina con actividad inhibitoria de tafia, composiciones farmaceuticas que los contienen y su uso como agentes terapeuticos o profilacticos para enfermedades tromboticas
AR079266A1 (es) Derivados de azabiciclo[3.2.0]hept-6ilo, procedimiento de preparacion de los mismos, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
CU20090143A7 (es) Derivados de ciclohexil-amida del ácido aril-carboxílico
CU20100179A7 (es) Piridinas y pirazinas como inhibidores de p13k